论文部分内容阅读
目的观察吉西他滨联合卡培他滨方案治疗转移性胃癌的近期疗效和不良反应。方法选择60例未手术的转移性胃癌患者,随机分为两组,每组30例,第一组采用吉西他滨联合卡培他滨化疗方案,吉西他滨1000mg/m2持续静脉滴注30min,第1、8天;卡培他滨1000mg/m2口服,2次/d,第1～14天。第二组单用卡培他滨,卡培他滨1000mg/m2口服,2次/d,第1～14天。3周为1个疗程,2个疗程后行疗效评价。结果第一组有效率(RR)33.3%,疾病控制率(DCR)80%,中位缓解期4.5个月,中位生存期12.9个月;第二组RR和DCR仅为20%和60%,其中位缓解期和中位生存期分别为3.5月和10.7月。第一组骨髓抑制率显著高于第二组,而在手足综合征方面,两组差异无统计学意义。结论吉西他滨+卡培他滨化疗方案二线治疗转移性胃癌有一定疗效,不良反应可耐受,疾病控制率高。
Objective To observe the short-term efficacy and side effects of gemcitabine and capecitabine in the treatment of metastatic gastric cancer. Methods Sixty patients with metastatic gastric cancer without surgery were randomly divided into two groups (30 in each group). The first group received gemcitabine combined with capecitabine chemotherapy, and the gemcitabine 1000 mg / Day; capecitabine 1000mg / m2 orally, 2 times / d, the first to 14 days. The second group with capecitabine alone, capecitabine 1000mg / m2 orally, 2 times / d, 1 to 14 days. 3 weeks for a course of treatment, 2 courses after the curative effect evaluation. Results The first group had an effective rate (RR) of 33.3%, a disease control rate (DCR) of 80%, a median remission of 4.5 months and a median of 12.9 months. In the second group, RR and DCR were only 20% and 60% , Which median remission and median survival were 3.5 months and 10.7 months. The first group of bone marrow suppression was significantly higher than the second group, while in hand-foot syndrome, the two groups showed no significant difference. Conclusions Gemcitabine + capecitabine chemotherapy regimen has a certain curative effect on second-line treatment of metastatic gastric cancer, with adverse reactions tolerated and disease control rate high.